Coastal Meds LLC, which compounds drugs as an outsourcing facility, has voluntarily recalled all of its products marketed as sterile due to visible particles in some of the drug vials for injection, the Food and Drug Administration announced Friday. Health care providers should immediately quarantine and not administer any Coastal Meds sterile drug products intended for injection, FDA said. The agency encourages health care professionals and patients to report any adverse reactions or quality problems to the MedWatch program.  

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…